

## INDEX

*Note: Page numbers in italics indicate a figure and page numbers in bold indicate a table.*

- Abstract models, 14, 18–19
- ACE inhibitors, 120–121
- Acetylcholine, 155, 158
- Acetylcholinesterase (AChE) inhibitors, 158
- Acquired immunodeficiency syndrome (AIDS), 66, 113–115
- Aducanumab (Aduhelm™), 4, 159
- Adverse outcome pathways, 34, 101
- African Americans, personalized medicine and, 9–11
- African sleeping sickness, 111
- Albino rats, creation of, 55
- Allison, James P., 134, **211**
- Alpha-synuclein (aSyn), 54, 160–162
- ALS. *See* Amyotrophic lateral sclerosis (ALS)
- Alteplase, 124
- Alzheimer's disease
- amyloid cascade hypothesis of, 155, 159
  - characteristics of, 154–155
  - failure rate for drugs targeting, 4
  - homologous disease genes, 29
  - mouse models of, 155–159, 157, 172, 187, 192, 196, 199
  - organoids for, 97
  - sex differences in, 140
- American Type Culture Collection, 90
- Ames mutagenesis test, 100–101
- Aminopterin, 129
- Amyloid cascade hypothesis, 155, 159
- Amyloid precursor protein (APP), 155, 199
- Amyotrophic lateral sclerosis (ALS)
- familial versus sporadic, 145
  - Ice Bucket Challenge for, 154
  - models for, 152–154
  - replicability of therapies for, 5, 6
- Androgen deprivation therapy, 127
- Angina pectoris, 120–121
- Angioplasty, 123–124
- Angiotensin-converting enzyme, 121. *See also* ACE inhibitors
- Animal models, 1, 14–15. *See also* Animal welfare; *Caenorhabditis elegans* (roundworm); Chickens; Dogs; *Drosophila melanogaster* (fruit flies); Guinea pigs; Marmosets; Mouse (mice); Pigs; Primates (non-human); Rabbits; Rat(s); Zebrafish (*Danio rerio*)
- in ancient Greece and Rome, 45–46
  - biological variation in, 6–8
  - drug clearance and absorption in, 65
  - dual-species approach to, 136–138
  - in early experimental physiology and medicine, 46–51
  - ethical questions surrounding, 1–3, 37–39
  - historical fluctuations in popularity of, 75–76, 103–104
  - limitations of, 11–13, 135–138
  - in nontranslational research, 74–75
  - relative distribution of model species in, 43–45, 44, 52
  - selection of research animals for, 191–194
  - standardization in, 194–197, 195
  - strain differences in, 191–192
  - 3R (replace, reduce, refine) approach to, 2, 137, 176
  - in toxicology testing, 99–100, 99

- Animal rights activists, 3, 171
- Animal welfare, 34–40  
 attribution of sentience and, 35–36  
 conflicting attitudes toward, 37–40  
 history of, 35  
 laws and regulations related to, 36–37, 50–51  
 model selection and, 105, 176–179  
 “phylogenetic scale,” notion of, 35–36
- Animal Welfare Act, 36–37, 50–51, 63
- Antibiotics, 49, 111–113, 136
- Antidepressants, 163–165
- Antifolate compounds, 129
- Antipsychotic drugs, 168–169
- Antitestosterone drugs, 127
- Antiviral drugs, 113–115
- Anti-vivisection movement, 1, 2, 39, 47, 176
- Anxiety disorders, 139, 140
- Apolipoprotein E, 155
- Applied science, 3
- Aristotle, 45, 69
- Arrhythmia, 118
- Arsphenamine, 111
- Aspirin, 98, 124, 189
- Atherosclerosis, 121–124
- Atypical antipsychotics, 168–169
- Autism spectrum disorder, 32–33, 140
- Azidothymidine (AZT), 114
- Azo dyes, 113
- Baboons, at University of Pennsylvania, 63–64, 141
- Bacillus Calmette–Guérin (BCG) vaccine, 109
- Bacon, Francis, 41, 198–199
- Bacteria, 79–81  
*Escherichia coli*, 29, 51, 78–81, 109–110, 129  
*Mycobacterium tuberculosis*, 109 (see also tuberculosis)  
*Salmonella typhimurium*, 78, 100  
*Staphylococcus*, 112  
 streptococcal, 113  
 synthetic, 20  
*Treponema pallidum*, 111  
*Vibrio natriegens*, 79
- Bacteriophages, 81–83
- Basic science, 3
- Bayer Health Care, 6
- Beach, Frank, 56
- Behaviorism, 41
- Bentham, Jeremy, 35
- Benzer, Seymour, 32, 53, 106
- Bernard, Claude, 1, 13, 186
- Beta-amyloid, 155–156, 158–159
- Beta-blockers, 120–121
- BiDil, 10
- Big-tent biology, 189–190
- Biological complexity, in models, 31–34, 201–205
- Biological hierarchies, 27–31
- Biological variation, 6–8  
 model selection and, 13–14  
 personalized medicine, 9–11, 132–133  
 sex differences and, 9, 140  
 TGN1412 trial, 11–13, 66, 176, 186
- Biomarkers, 11–12, 21
- Biomass, global distribution of, 78
- Biomedical research, crises in, 1–3  
 replicability crisis, 5, 6–8  
 translatability crisis, 3–6, 5
- Bipolar disorder, 140, 165–166
- Birds, 38
- Black-6 mouse (C57BL/6), 57, 192
- Blacks/African Americans, personalized medicine and,  
 9–11
- Blue baby syndrome, 50
- Box, George, 17, 21
- Brain injury. See Traumatic brain injury (TBI)
- Breast cancer, 127–128, 131, 132
- Brenner, Sydney, 74, 210
- Broca, Paul, 47
- Bush, George W., 94
- C9orf72*, 152–154
- Cade, John, 166, 170
- Caenorhabditis elegans* (roundworm)  
 genetic similarity and phylogenetic relationship,  
 72–73  
 as model organism, 23, 73–74, 100, 137, 149
- Callithrix jacchus* (marmoset), 67
- Cancer  
 animal and cell culture models for, 15, 57–58, 69, 71,  
 135–138  
 chemotherapy for, 128–133  
 comparative approach to, 91, 189  
 failure rate for drugs targeting, 4  
 history of, 125–126  
 hormone therapy for, 127–128  
 immunotherapy for, 133–135, 134

- Peto's paradox of, 189
- radiation therapy for, 126–127
- replicability crisis and, 6
- Captopril, 121
- Cardiovascular therapies, 118–125
  - atherosclerosis, 121–124
  - failure rate for, 4
  - heart medications, 10, 118–121
  - patterns of model use for, 135–138
  - stroke and neuroprotection, 124–125
- Carrel flasks, 87
- Cats
  - Animal Welfare Act protections of, 36–37, 51
  - drug clearance and absorption in, 189
  - genetic similarity and phylogenetic relationship, 25, 26
  - as research animals, 38, 45, 51, 120, 143
- Cattle
  - E. coli* in, 79
  - genetic similarity and phylogenetic relationship, 25, 26
  - as research animals, 109, 123
- Cattle anthrax, 49, 108
- Causal drift, 203
- CD28 signaling molecule, 11–13, 186
- Cell and tissue culture models, 85–98
  - advantages of, 178
  - for amyotrophic lateral sclerosis, 153–154
  - complex culture systems, 96–98
  - continuous cell lines, 89–93, 92
  - dissociated cell cultures, 88–89
  - hanging drop cultures, 86, 87
  - for HIV/AIDS, 113–115
  - for infectious disease, cardiovascular disease, and cancer, 135–138
  - microfluidic devices, 96
  - organoids, 97–98
  - organotypic slice cultures, 86–88, 87
  - selection of research cells, 191–194
  - sex differences in, 193–194
  - stem cells, 93–96, 151–154
  - three-dimensional, 96–97
  - for vaccine development, 109–111
- Central nervous system (CNS) injury
  - spinal cord injury, 141–143
  - traumatic brain injury, 63–64, 141–143
- Cephalopods, 36–37
- Cerebral cortex, 47, 63–64, 97, 152
- Chain, Ernst B., 107, 112, 208
- Checkpoint inhibitors, 133–135, 134
- Chemotherapy
  - general, 164
  - targeted, 130–133
- Chicken cholera, 49, 108
- Chickens
  - attitudes toward, 39
  - excluded from US Animal Welfare Act, 37
  - genetic similarity and phylogenetic relationship, 26
  - as research animals, 23, 44, 69, 122
- Chimpanzees, 64–67, 113, 156
- Chlorpromazine, 164, 168, 170
- Cholesterol and cholesterol-lowering drugs, 121–122
- Cholinergic neurons, 158
- Circle of Willis, 124
- Circulatory system, Harvey's studies of, 46. *See also*
  - Cardiovascular therapies
- Cisplatin, 129, 130
- Clemizole, 72
- Clinical trials
  - failures, learning from, 16, 197–198
  - improvement of, 183
- Clozapine, 168–169
- Coenzyme Q10, 150–151
- Cognitive dissonance, 37–40
- Cold stress, in mice, 22, 24
- Compactin, 122, 136
- Comparative biology
  - model selection and, 184–189
  - philosophy of models in, 40–41
- Complexity, 16
  - approach to, 201–205, 204
  - complex culture systems, 96–98
  - endophenotypes, 32–33
  - systems biology, 33–34
- Congestive heart failure, 120
- Constraint-induced movement therapy, 63
- Constraints on generality (COG) statements, 8
- Construct validity, 21
- Context-dependence, 203–205, 204
- Continuous cell lines, 89–93, 92
- Cosmetics testing. *See* Toxicology
- COVID-19 pandemic, 39, 62, 110
- Cowpox, 108
- Creatine, 5, 151

- Crises in biomedical research. *See* Biomedical research, crises in
- CRISPR/Cas9 gene, 83
- Cruelty to Animals Act (1876), 36, 50
- CTLA-4, 133–135, 134
- Cullen, Charles E., 120
- Cyclophosphamide, 129
- Cytokines, TGN1412 monoclonal antibody and, 11–13
- Danio rerio*. *See* Zebrafish (*Danio rerio*)
- Davis, Rowland, 40, 51
- Declaration of Helsinki, 179
- Deep brain stimulation (DBS), 161–162
- Deep homology, 28
- Degus, Alzheimer's research in, 158
- Delbrück, Max, 82, **209**
- Depression, 140, 162–165
- D'Hérelle, Felix, 172
- Dialectical approach, 189–190
- Digoxin/digitalis, 118–119
- Diphtheria, 48
- Disease genes, 27–31, 30, 199
- Diseases. *See* Cancer; Cardiovascular therapies; Infectious disease therapies; Neurological disorders
- Disrupted in schizophrenia-1 (DISC1)*, 167
- Dissociated cell cultures, 88–89
- Diversity, 16, 185, 198–201
- Dogs
- Animal Welfare Act protections of, 36–37
  - cancer research in, 127
  - cardiovascular research in, 120, 122, 123
  - drug clearance and absorption in, 186, 189
  - in early experimental medicine, 47, 50–51
  - genetic similarity and phylogenetic relationship, 25–27, 26, 181, 182
  - mutations in hypocretin receptor gene in, 33
  - popularity as research animals, 1, 38, 44, 45, 50–51, 52
  - spinal cord injury research in, 143
  - toxicology testing in, 99, 100
  - tuberculosis research in, 109
  - vaccine development in, 110
- Domagk, Gerhard, 113, **208**
- Donepezil, 158
- Dopamine, 149, 160–163, 168
- Dopamine receptor blockers, 168–169
- Down's syndrome, 199
- Draize eye test, 50, 102
- Dravet syndrome, 71–72
- Drosophila melanogaster* (fruit flies)
- comparative studies of, 200
  - homologous disease genes in, 28–29
  - as research animals, 23, 44, 51–54, 137, 146, 151, 160–161
- Drug clearance and absorption
- in animal models, 65
  - comparative approach to, 187–189, 188
- Drug dose scaling, 187–189, 188
- Dual-species approach, 136–138
- Eating disorders, 140
- Ecology, of model systems, 75–76
- Edaravone, 154
- Ehrlich, Paul, 49, 111, 135, 136, **207**
- Electroconvulsive therapy (ECT), 165
- Embryonic stem cells (ESCs), 93–96
- Embryos
- chicken, 69
  - human, 94
  - zebrafish, 70
- Enalapril, 121
- Endophenotypes, 32–33, 172–173
- Environmental toxicology. *See* Toxicology
- Epilepsy
- Huntington's disease and, 148
  - zebrafish models of, 71
- EPX-100, 72
- Erythropoietin, 142
- Escherichia coli*
- emergence as model species, 78–81
  - homologous disease genes, 29
  - platinum-related drug research in, 129
  - supermodel status of, 51
  - vaccine development in, 109–110
- Estrogen, 127, 131
- Ether anesthesia, 46
- Eukaryotes, 77, 78, 83, 84, 106. *See also* Yeast
- Evolution
- material models and, 20
  - molecular conservation in, 27–31
  - of multicellularity, 77, 78
- Experimental convenience, 76, 104, 105, 137
- Experimental physiology, history of, 46–47
- Extrapolator's circle, 20, 180

- Face validity, 21
- Farm animals. *See also Individual animals*
- attitudes toward, 39
  - excluded from US Animal Welfare Act, 37
  - as research animals, 38, 52, 127
- Female subjects, representation of, 9
- Feynman, Richard, 14
- Fibroblasts, 89
- Fidelity of model systems, 177–178
- Fish. *See Zebrafish (Danio rerio)*
- Fisher, Ronald, 196
- 5-fluorouracil, 129–130
- Fleming, Alexander, 111, **208**
- Florey, Howard, 112, **208**
- Fluoxetine, 164–165
- Flu vaccine development, 69
- Folic acid inhibitors, 129
- Food and Drug Administration (FDA), 3, 4, 10, 50, 122, 128, 142, 150, 159, 162, 164
- Foxglove (*Digitalis purpurea*), 118
- Frogs
- hanging drop cultures developed from, 86
  - popularity as model organism, 1, 23, 46–47
- Fruit flies. *See Drosophila melanogaster* (fruit flies)
- Functional localization, in cerebral cortex, 47
- Galen, 1, 45–46
- Galtier, Pierre-Victor, 49
- Gardasil, 109–110
- Gefitinib, 197
- Gene cloning, 83, 84
- Generalization, from models to humans, 6–8
- dangers of, 11–13
  - model selection and, 13–14
  - personalized medicine, 9–11, 132–133
  - sex differences and, 9, 140
  - TGN1412 trial case study, 11–13, 66, 176, 186
- Genetic modification, 22–25, 152
- of cell lines, 90
  - of chickens, 69
  - of non-human primates, 67
  - of mice, 57–60, 130–131, 146–151, 153, 155, 158–160, 191–192, 195
- Genetic similarity
- model selection and, 180–181, 182
  - nepotist's perspective on model selection, 180–181, 182
  - phylogenetic distance versus, 25–27, 26
- Geology, material models in, 19
- Gerbils, stroke research in, 124
- Getting, Peter, 186
- Gleevec, 132
- Glial cells, 145
- Great Ape Protection Act, 66
- Greece (ancient), studies of animals in, 45–46
- Guide for the Care and Use of Laboratory Animals*, 2, 177
- Guinea pigs
- Animal Welfare Act protections of, 36–37
  - in early experimental medicine, 48–49
  - penicillin toxicity in, 112–113, 112, 136
  - as research animals, 43, 44, 48–49, 52, 99, 109, 120–121, 137
- Haloperidol, 168
- Hamsters
- Animal Welfare Act protections of, 36–37
  - continuous cell lines from, 90
  - as research animals, 43, 52
- Hanging drop cultures, 86, 87
- Harrison, Ross, 86
- Harvey, William, 46
- Hata, Sahachiro, 49, 111
- Health disparities, 10
- Heart medications, 10, 118–121
- Heath, Robert, 179
- HeLa cells, 90, 91, 193
- Helsinki, Declaration of, 179
- Hemodialysis, 50
- Hepatitis C, 64, 181
- Hepatitis C virus (HCV), 66, 114–115
- Hepatocytes, in vitro toxicity testing in, 101
- Herceptin, 132
- Hering, Constantin, 120, 138
- Herskowitz, Ira, 59
- Hierarchies, biological, 27–31
- High-density lipoprotein (HDL), 122
- High-fidelity fallacy, 27
- Hodgkin, Alan Lloyd, 19, **209**
- Hodgkin's disease, 129
- Honjo, Tasuku, 134, **211**
- Hormone therapy, 127–128
- Horses, 37, 38
- Huggins, Charles, 127, **209**
- Human immunodeficiency virus (HIV), 64, 66, 113–115, 181

- Human papilloma virus (HPV), 109–110
- Huntingtin (htt)*, 29–31, 30, 54, 146–152, 150, 202
- Huntington's disease
- CAG repeat length in, 146–149, 147
  - cell and tissue culture models of, 151–152
  - coenzyme Q10 trials for, 150–151
  - description of, 146
  - homologous disease genes and proteins, 29–31, 30
  - induced pluripotent stem cells and, 194
  - in vivo models of, 54, 146–151, 147, 150
  - Selisstat trials for, 151
  - tetrabenazine trials for, 149–150
- Huxley, Andrew Fielding, 19, **209**
- Hybridoma cell lines, 90
- Hydrogen sulfide, 59
- Hypocretin, 33
- Imatinib, 132
- Imipramine, 164, 170
- Immunotherapy, 133–135, 134
- Inbreeding, 22–25
- comparative research of, 200–201
  - Drosophila melanogaster* (fruit flies), 53
  - mice, 57, 130–131
  - rats, 55
  - zebrafish, 69
- Induced pluripotent stem cells (iPSCs), 93–96, 144, 151–154, 194
- Infectious disease therapies, 15
- antibiotics, 111–113
  - antiviral drugs, 113–115
  - patterns of model use for, 135–138
  - sepsis, 116–118, 117
  - vaccines, 108–111
- Institutional animal care and use committees (IACUCs), 39–40
- In vitro fertilization (IVF), 94
- In vitro models, 14–15, 20, 77, 92. *See also* Microbial models
- advantages of, 178
  - cell and tissue culture models, 85–98
  - factors governing selection of, 103–106
  - historical fluctuations in popularity of, 103–104
  - in HIV/AIDS research, 114
  - in HPV vaccine development, 109–110
  - for infectious disease, cardiovascular disease, and cancer, 135–138
  - knowledge of cells in, 191–194
  - microbial models, 77–85
  - standardization in, 194–197
  - in toxicology, 98–103, 99
- In vivo models. *See* Animal models
- Iproniazid, 164, 170
- IPSc-derived microglia, 92
- Isograft models, 131
- Jackson Laboratory, 57, 126
- Jacob, François, 80–81, **209**
- Jenner, Edward, 108
- Ketamine, 165, 170
- Kinase inhibitors, 132, 154
- Kingsford, Anna, 39
- Kluyver, Alvert Jan, 27
- Koch, Robert, 48, 79, 109, **207**
- Krebs, Hans, 20, 28, **208**
- Krebs, John, 28, 40
- Krogh, August, 19–20, 40–41, 53, 104, 171, 186, 205, **207**
- Krogh organisms, 40, 74, 104
- Krogh's principle, 19–20, 40–41, 67, 104, 171
- Laborit, Henri, 168
- Lacks, Henrietta, 90
- Lambda* phage, 83
- Lange, Frederik, 166
- L-dopa, 161
- Lederberg, Joshua, 106, **208**
- Legislation
- Animal Welfare Act, 36–37, 50–51, 63
  - Cruelty to Animals Act, 36, 50
  - Great Ape Protection Act, 66
  - NIH Revitalization Act (1993), 9–10
- Lehrman, Daniel, 41
- Leucine-rich repeat kinase 2 (LRRK2), 160
- Leukemia, 129
- Levi-Montalcini, Rita, 86, **210**
- Lewy bodies, 159–160
- Lipopolysaccharides (LPS), 163
- List of Essential Medicines (WHO), 129–130
- Lithium, 5, 48–49, 154, 166
- Little, C. C., 57, 59, 126
- Lobotomies, 167–168

- Lou Gehrig's disease. *See* Amyotrophic lateral sclerosis (ALS)
- Lovastatin, 122–123
- Low-density lipoprotein (LDL), 122
- LRRK2*, 160
- Luria, Salvador E., 32, **209**
- Lymphosarcoma, 129
- Macacine herpes virus, 67
- Macaque monkeys. *See also* Primates (nonhuman)  
drug clearance and absorption in, 65  
Galen's and Vesalius's studies of, 46  
genetic similarity and phylogenetic relationship, 182  
neurofibrillary tangles in, 156  
popularity as model organism, 44  
as research animals, 11–13, 60, 64, 114, 143, 146
- Macchiaroni, Paolo, 179
- Major depressive disorder, 140, 162–165
- Marmosets, 67, 146, 180
- Marsilid, 164
- Masitinib, 154
- Material models, 14  
characteristics of, 19–20  
modification of, 22–25  
scope and validation of, 20–21
- Mathematical models, 18–19, 34
- Matthew effect, 106
- Memantine, 158
- Messenger RNA (mRNA), 82, 110
- Methotrexate, 129–130
- Methylprednisolone, 144–145
- Microbial models, 77  
bacteria, 79–81  
evolution of multicellularity in, 77, 78  
global distribution of biomass, 78  
viruses, 81–83  
yeast, 84–85
- Microfluidic devices, 96–97
- Microglia, 145, 154
- Middle East respiratory syndrome coronavirus (MERS-CoV), 115
- Mini-brains, 97–98
- Minipigs. *See* Pigs
- Minocycline, 5
- Minority groups, personalized medicine and, 9–11
- Misleading models, 170–172
- Model fidelity, assumptions about  
biological hierarchies and disease genes, 27–31, 30  
similarity versus phylogenetic distance, 25–27, 26
- Model organisms, 17  
comparative approach to, 184–185  
genetic modification of, 22–25  
in nontranslational research, 74–75  
popularity and relative distribution of, 23, 43–45, 44  
problems with, 20
- Model selection, 13–14, 175–176  
animal welfare perspective on, 176–179  
biological variation and, 13–14  
challenges of, 190–191, 205–206  
comparative biology perspective on, 184–189  
complexity and, 201–205  
dialectical approach to, 189–190  
factors governing, 103–106  
knowing one's research animals and cells, 191–194  
nepotist's perspective on, 180–181, 182  
pragmatic optimist perspective on, 181, 183–184  
standardization and, 194–197
- Model systems, 13–16, 175–176. *See also* Philosophy of models  
abstract, 14, 18–19  
classification schemes, 17–18  
factors governing selection of, 103–106  
material, 14, 19–25  
partial, 172–173  
scope of, 104
- Molecular conservation, 27–31
- Monkeys. *See also* Primates (nonhuman)  
controversies engendered by, 62–64, 141  
drug clearance and absorption in, 65  
genetic similarity and phylogenetic relationship, 182  
macaque. *See* Macaque monkeys  
neurofibrillary tangles in, 156  
popularity as model organism, 44  
as research animals, 60–62, 100, 109–110, 115, 122, 151, 162  
rhesus, 109  
TGN1412 trial case study, 11–13  
transgenic, 151
- Monoamine oxidase inhibitors, 164
- Monoclonal antibodies, 11–13
- Monod, Jacques, 27, 77, 80, **209**
- Morgan, Thomas H., 53, **208**

- Moulton, John Fletcher, 179
- Mouse (mice). *See also* Mouse models  
 cold stress in, 24  
 continuous cell lines from, 90  
 emergence as model organism, 22–25, 23, 44, 57–60, 75–76, 137, 178  
 excluded from US Animal Welfare Act, 37  
 genetic similarity and phylogenetic relationship, 25–27, 26, 181, 182  
 homologous disease genes in, 29–31, 30  
 inbred and genetically modified strains of, 57–60, 130–131, 148, 153, 155, 160, 191–192, 195  
 numbers used for research, 38, 52  
 strain differences in, 171, 191–192, 195
- Mouse lemurs, neurodegeneration in, 156
- Mouse models, 57–60  
 Alzheimer's disease, 155–159, 157, 172, 187, 192, 196, 199  
 amyotrophic lateral sclerosis (ALS), 153  
 antibiotics, 113  
 atherosclerosis, 123–124  
 bipolar disorder, 166  
 cancer, 126–132, 134  
 hepatitis C, 115  
 HIV/AIDS, 114  
 Huntington's disease, 146–151, 147, 150  
 Parkinson's disease, 160–162  
 schizophrenia, 167–169  
 sepsis, 116–118, 117  
 spinal cord injury, 143  
 stroke, 124  
 toxicology testing, 99  
 tuberculosis, 109
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 160–161, 200
- Multicellularity, evolution of, 77, 78
- Multiple myeloma, 197
- Multiple sclerosis, 140
- Multitarget drugs, 203–205
- Murrell, William, 120, 138
- Mustard agents, 128–129
- Mutant strains  
 of *Caenorhabditis elegans* (roundworm), 72  
 of *Drosophila melanogaster* (fruit flies), 53  
 of *Escherichia coli*, 80  
 of mice, 58–59, 192  
 of *Salmonella typhimurium*, 100  
 of yeast, 84  
 of zebrafish, 69–70
- Myc*, 202
- Mycobacterium tuberculosis*, 109
- Naked mole rats, 200
- Narcolepsy, 33
- Nematodes. *See Caenorhabditis elegans* (roundworm)
- Nepotist's perspective, 180–181, 182
- Nerve growth factor (NGF), 86, 159
- Neurodegenerative disorders, 145–146  
 Alzheimer's disease, 4, 29, 97, 140, 154–159, 157, 172, 187, 192, 196, 199  
 Amyotrophic Lateral Sclerosis, 152–154  
 Huntington's disease, 29–31, 30, 54, 146–152, 147, 150, 194  
 Parkinson's disease, 140, 158–162, 200
- Neurofibrillary tangles, 155, 156, 158
- Neurological disorders, 15  
 challenges of, 169–170  
 disability costs of, 139–141, 140  
 endophenotypes, 172–173  
 misleading models of, 170–172  
 neurodegenerative disorders, 145–162  
 neuropsychiatric disorders, 162–169  
 partial models, 172–173  
 role of serendipity in, 170  
 sex differences in, 140  
 spinal cord injury, 142–145  
 traumatic brain injury, 63–64, 141–143
- Neuroprotection, 124–125
- Neuropsychiatric disorders  
 bipolar disorder, 165–166  
 definition of, 162  
 major depressive disorder, 162–165  
 schizophrenia, 164, 166–169, 173
- NIH Revitalization Act (1993), 9–10
- Nitrogen mustard, 128–129
- Nitroglycerin, 120, 138
- N*-methyl-d-aspartic acid (NMDA) receptor blocker, 158, 165
- Nobel Prize in Physiology or Medicine, winners of, 207–211. *See also Individual scientists*
- Nogo-A, 143–144
- Nontranslational research, animal models in, 74–75
- Norepinephrine, 149, 161, 163
- Nüsslein-Vollhard, Christiane, 53, 210



- Oligonucleotides, 152
- Oncogenes, 126
- Oncomice, 130–131
- Orexin, 33
- Organoids, 97–98
- Organotypic slice cultures, 86–88, 87
- Organs-on-a-chip, 96, 105, 177
- Owls, 104
  
- Pan troglodytes*. *See* Chimpanzees
- Paramecium, 104
- Paraquat, 160
- PARK8*, 160
- Parkinson's disease (PD), 140, 158–162, 200
- Partial models, 172–173
- Pasteur, Louis, 3, 48, 49, 79, 108, 170
- Pax-6*, 28
- PC12 cells, 91, 93
- PCSK9, 123
- PD-L1, 133–135, 134
- Penicillin, 49, 111–113, 136
- People for the Ethical Treatment of Animals (PETA), 37
- Personalized medicine, 9–11, 132–133
- Perspectives on models, 175–176
  - animal welfare, 176–179
  - comparative biology, 184–189
  - dialectical approach, 189–190
  - nepotist, 180–181, 182
  - pragmatic optimist, 181, 183–184
- Peto's paradox, 189
- Phages, 81–83
- Philosophy of models, 14, 190–191
  - abstract models, 18–19
  - animal welfare, 34–39
  - comparative biology and, 40–41
  - complexity in, 31–34, 201–205, 204
  - diversity and, 198–201
  - knowledge of research animals and cells in, 191–194
  - Krogh's principle, 19–20, 40–41, 67, 104, 171
  - material models, 19–25
  - model fidelity, 25–31
  - standardization, 17–18, 194–197, 195
- Phylogenetic relationship
  - genetic similarity versus, 25–27, 26
  - nepotist's perspective on model selection, 180–181, 182
- Phylogenetic scale, 2, 35–36, 40, 177, 181
  
- Physiology
  - comparative, 41
  - experimental, 46–47
- Pigs
  - attitudes toward, 39
  - genetic similarity and phylogenetic relationship, 25–27, 26, 68, 181, 182
  - as research animals, 64, 68, 100, 123, 142, 146
  - skin permeability to various compounds in, 65
- Pit viper venom, ACE inhibitors developed from, 121
- Plaque. *See* Atherosclerosis
- Platinum-containing drugs, 129
- Plato, 35
- Polio vaccine development, 60–62, 136
- Polyclonal antibodies, 50
- Polymerase chain reaction (PCR) technique, 104
- Pragmatic optimist perspective, 181, 183–184
- Precision medicine. *See* Personalized medicine
- Preclinical research
  - improvement of, 183–184
  - streetlight effect in, 171, 184
- Predictive validity, 21
- Prefrontal lobotomies, 167–168
- Presenilin, 155–156
- Primates (nonhuman), 60–67, 156. *See also* Chimpanzees; Monkeys
  - Animal Welfare Act protections of, 36–37
  - controversies engendered by, 62–64
  - drug clearance and absorption in, 65
  - genetic similarity and phylogenetic relationship, 25–27, 26, 60, 180–181, 182
  - numbers of animals used for research, 52, 60
  - popularity as model organism, 137
  - as research animals, 38, 60–62, 100, 109–110, 115, 122, 146, 162
  - simian immunodeficiency virus in, 113
  - TGN1412 trial case study, 11–13
- Principles of variation, 187
- Progesterone, 142
- ProHema, 71
- Promethazine, 168
- Prontosil, 113
- Propranolol, 120–121
- Prostate cancer, 127, 132
- Proto-oncogenes, 126
- Prozac, 164–165

- PTEN (phosphatase and tensin homolog), 144  
Publication bias, 5
- R6/2 mice, 30, 146, 147, 151, 171
- Rabbits  
Animal Welfare Act protections of, 36–37  
drug clearance and absorption in, 188, 189  
in early experimental medicine, 47, 49–50  
popularity as model organism, 43, 44, 52, 137  
as research animals, 1, 49–50, 102, 110, 111, 113, 122, 126, 128–129  
skin permeability of, 65
- Rabies vaccine development, 49, 108
- Radiation therapy, 126–127
- Rat(s). *See also* Rat models  
albino strains of, 55  
drug clearance and absorption in, 188, 189  
emergence as first standardized mammal, 54–57  
excluded from US Animal Welfare Act, 37  
genetic similarity and phylogenetic relationship, 25–27, 26, 54–55  
popularity as model organism, 22–25, 23, 38, 44, 55–57, 75–76
- Rat models, 55–57  
ACE inhibitors, 121  
amyotrophic lateral sclerosis (ALS), 149  
cancer, 127–128  
central nervous system injury, 142  
hepatitis C virus, 115  
Parkinson's disease, 162  
schizophrenia, 167  
spinal cord injury, 143  
stroke, 124  
toxicology, 99
- Receptor tautology, 21
- Recombinant inbred strains, 200–201
- Reduction of animal numbers, 2, 176
- Reference species, 185
- Refinement of experiments, 2, 176
- Regulations, animal welfare, 36–37
- Regulatory approval process, 3–6
- Remdesivir, 115
- Replacement of sentient animals, 2, 176–177
- Replicability crisis, 5, 6–8
- Representational scope, 104
- Reserpine, 161, 163
- REST (repressor element-1 silencing transcription factor), 202
- Retinoblastoma (Rb)* gene, 202
- Reverse translation, 197–198
- Rheumatoid arthritis, 4, 11
- Riluzole, 5, 154
- Rome, ancient  
killing of animals in, 35  
studies of animals in, 45–46
- Rosenberg, Barnett, 129
- Rotenone, 160
- Roundworm. *See Caenorhabditis elegans* (roundworm)
- Rous sarcoma virus, 81–83, 126
- Sabin, Albert, 61–62
- Saccharomyces cerevisiae* (budding yeast), 84–85
- Salmonella typhimurium*, 78, 100
- Salvarsan, 49, 111
- SARS-CoV-2, 110, 115. *See also* COVID-19 pandemic
- Schizophrenia, 164, 166–169  
animal models of, 167–169, 172  
definition of, 166  
endophenotype approach to, 32–33  
Research Domain Criteria framework and, 173
- Schizosaccharomyces cerevisiae*, 201
- Schizosaccharomyces pombe*, 85, 201
- Schou, Mogens, 166
- Scope  
of material models, 19–20  
of model systems, 104
- Scurvy, 48
- Sea anemones, homologous disease genes in, 28–29
- Selisistat, 151
- Sentient animals, replacement of, 2, 35–36, 176–177
- Sepsis, 116–118, 117
- Serendipity, role of, 170
- Serotonin, 149, 163–164, 168–169
- Serotonin reuptake inhibitors (SRIs), 164–165
- Serum therapy, 109
- Sex differences  
in neurological disorders, 140  
research implications of, 9, 203
- Silver Spring monkeys case, 62–64
- Simeprevir, 115
- Simian immunodeficiency virus (SIV), 113
- Sirtuin inhibitors, 151
- Skin permeability, in animal models, 65

- Sloppy control, 34, 203–205, 204
- Small-molecule drugs, 132
- Smallpox, 108
- Sociological factors in model selection, 105–106
- SOD1 (superoxide dismutase-1)*, 152–154, 199
- Sofosbuvir, 115
- Speciesism, 177
- Spinal cord injury (SCI), 142–145
- Standardization, 15–16, 194–197, 195
- Standardization fallacy, 196
- Staphylococcus*, 112
- Statins, 122–123, 136
- Stem cells/stem cell therapy, 93–96, 144, 151–154, 162, 194
- Stents, 123
- Streetlight effect, 171, 184
- Streptococcal bacteria, 113
- Stroke, 124–125
- Substantia nigra (SN), 159
- Sulfanilamide, 98, 113
- Supermodels, 51
- Superoxide dismutase-1 (SOD1)*, 152–154, 199
- Surrogate models, 17
- Swine flu, 49, 108
- Syphilis, 49, 111
- Systems biology, 33–34, 205
- Tamiflu, 115
- Tamoxifen, 127–128
- Targeted chemotherapy, 130–133
- Tau, 155–156
- Taub, Edward, 62–63
- T cells, TGN1412 monoclonal antibody and, 11–13
- T cell suppression, 133
- TDP43*, 152, 153
- Telomeres, 89, 189
- Tetrabenazine, 149–150, 170
- TGN1412 trial, 11–13, 66, 176, 186
- Thalidomide, 5, 98, 187, 197
- Theobromine, 186
- Thomas, Vivien, 50
- Thomas Aquinas (saint), 35
- 3R approach (replace, reduce, refine), 2, 137, 176
- Tiered research strategy, 178–179
- Tissue culture models. *See* Cell and tissue culture models
- Tobacco mosaic virus, 81
- Toxicology
  - adverse outcome pathways approach to, 33–34
  - animal models in, 69, 70–71, 73, 99
  - in vitro models in, 98–103, 99
- Transcriptome analyses, 7, 157, 197
- Transduction, 79
- Transgenic mice, 58, 148, 153, 155, 160
- Translatability crisis, 3–6, 5
- Translational research, 3–6
- Trastuzumab, 132
- Traumatic brain injury (TBI), 63–64, 141–142
- Tree shrews, 115
- Treponema pallidum*, 49, 111
- Trial failures, learning from, 197–198
- Tricyclic antidepressants, 164
- Triplet genetic code, 82, 82
- Tuberculosis, 48, 109, 164
- Tumor banks, 131
- Turing, Alan, 18–19
- Tusko (elephant), 187
- Tyramine, 164
- Vaccine development
  - COVID-19, 62, 110
  - diphtheria, 48
  - flu, 69
  - history of, 48, 108–111
  - human papilloma virus (HPV), 110
  - polio, 60–62, 136
  - rabies, 49
  - smallpox, 108
  - tuberculosis, 48, 109
- Validation criteria, model, 19–20
- van Behring, Emil, 48
- Variation, principles of, 187
- Vasotec, 121
- Vesalius, Andreas, 1, 46
- Vibrio natriegens*, 79
- Viruses, 81–83, 97. *See also Individual viruses*
  - antiviral drugs, 113–115
  - in vitro models, 81–83
- Vitamin C, 48
- von Behring, Emil, 109, **207**
- Wernicke, Carl, 47
- Wieschaus, Eric F., 53, **210**
- Wistar Institute rats, 55, 127–128

World Health Organization, List of Essential Medicines,  
129–130

Worms. *See Caenorhabditis elegans* (roundworm)

Xenograft models, 131–132

*Xenopus*, 23, 26

X-rays, 126–127

Yeast, 84–85

popularity as model organism, 22, 23, 44, 51

*Saccharomyces cerevisiae*, 84–85

*Schizosaccharomyces pombe*, 85, 201

Zebrafish (*Danio rerio*), 69–72

genetic similarity and phylogenetic relationship, 26,  
70

limitations of, 137

as research animals, 22, 23, 44, 69–72, 76, 99, 100

Zika virus, 60, 97

This is a section of [doi:10.7551/mitpress/14366.001.0001](https://doi.org/10.7551/mitpress/14366.001.0001)

# Model Systems in Biology

## History, Philosophy, and Practical Concerns

By: Georg Striedter

### Citation:

*Model Systems in Biology: History, Philosophy, and Practical Concerns*

By: Georg Striedter


DOI: [10.7551/mitpress/14366.001.0001](https://doi.org/10.7551/mitpress/14366.001.0001)

ISBN (electronic): 9780262370028

Publisher: The MIT Press

Published: 2022

The open access edition of this book was made possible by generous funding and support from MIT Press Direct to Open



The MIT Press

© 2022 Massachusetts Institute of Technology

This work is subject to a Creative Commons CC-BY-ND-NC license. Subject to such license, all rights are reserved.



The MIT Press would like to thank the anonymous peer reviewers who provided comments on drafts of this book. The generous work of academic experts is essential for establishing the authority and quality of our publications. We acknowledge with gratitude the contributions of these otherwise uncredited readers.

This book was set in Adobe Garamond Pro and Berthold Akzidenz Grotesk by Westchester Publishing Services.

Library of Congress Cataloging-in-Publication Data

Names: Striedter, Georg F., 1962– author.

Title: Model systems in biology : history, philosophy, and practical concerns / Georg Striedter.

Description: Cambridge, Massachusetts : The MIT Press, [2022] | Includes bibliographical references and index.

Identifiers: LCCN 2021033979 | ISBN 9780262046947 (hardcover)

Subjects: LCSH: Animal models in research. | Animal experimentation.

Classification: LCC R853.A53 S77 2022 | DDC 616.02/7—dc23

LC record available at <https://lccn.loc.gov/2021033979>